Explore the Latest #NephTrials Discussion on Dapagliflozin and CKD on the ISN’s Twitter Feed
The latest #NephTrials online discussion took place on March 10.
Access the Twitter thread here.
Twitter attendees joined Ron Gansevoort, Roberto Pecoits-Filho, Joel Topf, Manasi Bapat, and Swapnil Hiremath to discuss the RENAL LIFECYCLE trial.
The conversation examined the composite and secondary outcomes of a randomized control trial investigating the effects of dapagliflozin on people with severe chronic kidney disease (CKD).
